The colorectal adenoma-carcinoma sequence has provided a paradigmatic framework for understanding the successive somatic genetic changes and consequent clonal expansions that lead to cancer 1 . However, our understanding of the earliest phases of colorectal neoplastic changes-which may occur in morphologically normal tissue-is comparatively limited, as for most cancer types. Here we use whole-genome sequencing to analyse hundreds of normal crypts from 42 individuals. Signatures of multiple mutational processes were revealed; some of these were ubiquitous and continuous, whereas others were only found in some individuals, in some crypts or during certain periods of life. Probable driver mutations were present in around 1% of normal colorectal crypts in middle-aged individuals, indicating that adenomas and carcinomas are rare outcomes of a pervasive process of neoplastic change across morphologically normal colorectal epithelium. Colorectal cancers exhibit substantially increased mutational burdens relative to normal cells. Sequencing normal colorectal cells provides quantitative insights into the genomic and clonal evolution of cancer.
The colorectal adenoma-carcinoma sequence has provided a paradigmatic framework for understanding the successive somatic genetic changes and consequent clonal expansions that lead to cancer 1 . However, our understanding of the earliest phases of colorectal neoplastic changes-which may occur in morphologically normal tissue-is comparatively limited, as for most cancer types. Here we use whole-genome sequencing to analyse hundreds of normal crypts from 42 individuals. Signatures of multiple mutational processes were revealed; some of these were ubiquitous and continuous, whereas others were only found in some individuals, in some crypts or during certain periods of life. Probable driver mutations were present in around 1% of normal colorectal crypts in middle-aged individuals, indicating that adenomas and carcinomas are rare outcomes of a pervasive process of neoplastic change across morphologically normal colorectal epithelium. Colorectal cancers exhibit substantially increased mutational burdens relative to normal cells. Sequencing normal colorectal cells provides quantitative insights into the genomic and clonal evolution of cancer.
Sequencing of the genomes of over 20,000 cancers of several types has identified the repertoire of driver mutations in cancer genes that convert normal cells into cancer cells and revealed the mutational signatures of the underlying biological processes that generate somatic mutations 2, 3 . Cancers are, however, end stages of an evolutionary process that operates within populations of cells, and commonly arise through the accumulation of several driver mutations that engender a series of clonal expansions. Understanding this progression has depended on the identification of somatic mutations in morphologically abnormal neoplastic proliferations that represent intermediate stages between normal cells and cancer cells 1 .
As for most cancer types, the earliest stages of progression to colorectal cancer remain less well understood. The driver mutation that first sets a colorectal epithelial cell on the path to cancer is probably caused by mutational processes that also operate in normal cells and that we only understand to a limited extent. The nature and numbers of the earliest neoplastic clones with driver mutations-which conceivably are morphologically indistinguishable from normal cells-are similarly unclear. In large part, these deficiencies are due to the technical challenge of identifying somatic mutations in normal tissues, which are composed of myriad microscopic cell clones. Several different approaches have been adopted to address this challenge [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] , and have revealed the signatures of common somatic mutational processes in normal cells of the small and large intestine, liver, blood, skin and nervous system. Thus far, however, studies have not been of sufficient scale to characterize variation in signature activity or detect processes that occur less frequently [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . High proportions of normal skin, oesophageal and endometrial epithelial cells have been shown to be members of clones that already carry driver mutations 10, 11, 15, 16 , and large mutant clones have been detected in the blood [17] [18] [19] [20] . The extent of this phenomenon in the colon, an organ with a high incidence of cancer, has not been investigated.
Colonic epithelium is a contiguous cell sheet organized into around 15 million crypts, each of which is composed of about 2,000 cells 21 . Towards the base of each crypt, a small number of stem cells are found, which are ancestral to the maturing and differentiated cells in the crypt 22 . These stem cells stochastically replace one another through a process of neutral drift 23, 24 , such that all stem cells-and thus all cells-in a crypt derive from a single ancestral stem cell that existed in recent years [25] [26] [27] . The somatic mutations that were present in this ancestor are thus found in all of the approximately 2,000 descendant cells and can be revealed by DNA sequencing of an individual crypt. These stem cells are thought to be the cells of origin of colorectal cancers 28 . To characterize the earliest stages of colorectal carcinogenesis, we examined somatic mutational burdens, mutational signatures, clonal dynamics and the frequency of driver mutations in normal colorectal epithelium by sequencing individual colorectal crypts.
Somatic mutations and mutational signatures
We used laser-capture microdissection to isolate 2,035 individual colonic crypts from the normal epithelium of 42 individuals aged 11 to 78, of whom 15 had a history of colorectal cancer and 27 did not (Methods, Supplementary Table 1 ), and sequenced their genomes. The distribution of variant allele fractions (VAFs) from whole-genome sequencing of 571 individual crypts showed that crypts were derived from a single ancestral stem cell (Extended Data Fig. 1d ), and simulations indicated that about 90% of the mutations called were fully clonal (Supplementary Information). There was substantial variation in mutational burdens between individual crypts-for example, the mutational burden ranged from 1,508 to 15,329 for individuals in their sixties-and this was not obviously attributable to technical factors. To explore the biological basis of this variation we extracted mutational signatures and estimated the contribution of each to the mutational burden of every crypt (Methods, Supplementary Information).
Nine single-base substitution (SBS), six doublet-base substitution (DBS) and five small insertion and deletion (indel) (ID) mutational signatures were found. Of these, 14 closely matched (Methods) a known reference signature (SBS1, SBS2, SBS5, SBS13, SBS18, DBS2, DBS4, DBS6, DBS8, DBS9, DBS11, ID1, ID2 and ID5; nomenclature as described previously 2 ) and six did not (SBSA, SBSB, SBSC, SBSD, IDA and IDB) ( Fig. 1 
Ubiquitous mutational signatures
Eleven signatures (SBS1, SBS5, SBS18, DBS2, DBS4, DBS6, DBS9, DBS11, ID1, ID2 and ID5) were found in over 85% of crypts and are here termed 'ubiquitous'. All have been previously described 2 .
SBS1 is characterized by C>T substitutions at NCG trinucleotides (the mutated base is underlined) and is probably a result of the deamination of 5-methylcytosine. Its mutational load correlated linearly with age ( Fig. 2 ). There was, however, variation in SBS1 mutational burdens 0.00 0.02 0.04 0.06 0.08 0.10 0. 12   AC>CA  AC>CG  AC>CT  AC>GA  AC>GG  AC>GT  AC>TA  AC>TG  AC>TT  AT>CA  AT>CC  AT>CG  AT>GA  AT>GC  AT>TA  CC>AA  CC>AG  CC>AT  CC>GA  CC>GG  CC>GT  CC>TA  CC>TG  CC>TT  CG>AT  CG>GC  CG>GT  CG>TA  CG>TC  CG>TT  CT>AA  CT>AC  CT>AG  CT>GA  CT>GC  CT>GG  CT>TA  CT>TC  CT>TG  GC>AA  GC>AG  GC>AT  GC>CA  GC>CG  GC>TA  TA>AT  TA>CG  TA>CT  TA>GC  TA>GG  TA>GT  TC>AA  TC>AG  TC>AT  TC>CA  TC>CG  TC>CT  TC>GA  TC>GG  TC>GT  TG>AA  TG>AC  TG>AT  TG>CA  TG>CC  TG>CT  TG>GA  TG>GC  TG>GT  TT>AA  TT>AC  TT>AG  TT>CA  TT>CC  TT>CG  TT>GA  TT>GC T>A  C>T  C>G  T>C  T>G   AC>NN  AT>NN  CC>NN  CG>NN  CT>NN  G C>NN TA>NN  T C>NN  TG>NN  TT>NN   C  T  C  T  2  T  3  4  5+  2  3  4  5 +  2 3 Information) . SBS5 is a relatively featureless signature of unknown cause and SBS18 is characterized by C>A mutations, which may be caused by damage to DNA by reactive oxygen species 29, 30 . The mutational burdens of these two signatures correlated with age, with the same ordering of sector differences as SBS1 (P = 9.89× 10 −26 for SBS5; P = 5.43× 10 −22 for SBS18). Even after taking anatomical location and age into account, differences in mutational burden remained between different crypts, notably for SBS18 ( Fig. 2 , Extended Data Fig. 9 , Extended Data Fig. 6al ). Combining ubiquitous SBS mutational signatures, and averaging over anatomical sites, the rate of mutation was 43.6 mutations per year, which is comparable with previous estimates 4 . DBS2, DBS4, DBS6, DBS9 and DBS11 were tightly correlated in all colonic crypts. ID1, ID2 and ID5-which are characterized by indels of a single T and may be the consequence of slippage during DNA replication-all accumulated linearly with age, with the same order of sector differences as SBS1 (P = 1.66 × 10 −5 for ID1, P = 4.53 × 10 −6 for ID2 and P = 4.53 × 10 −6 for ID5) (Supplementary Information, Extended Data Fig. 5 ).
The correlations of ubiquitous signatures with age indicate that the mutational processes that underlie them operate throughout life, in all individuals and all colorectal stem cells. However, the results also suggest that differences in physiology and/or microenvironment (and, potentially, the age of the most recent common ancestor of the crypts 27 ) between different sectors of the colon cause measurable differences in somatic mutation rates.
Sporadic mutational signatures
Nine signatures (SBS2, SBS13, SBSA, SBSB, SBSC, SBSD, DBS8, IDA and IDB) were present only in a subset of individuals and/or a subset of crypts and are here termed 'sporadic'. All were novel, except for SBS2, SBS13 and DBS8. SBS2 and SBS13 are characterized by C>T and C>G mutations at TCN, are probably caused by cytidine deaminases of the APOBEC family and usually occur together 31, 32 . They were present in only two crypts (a colonic crypt (Extended Data Fig. 6ai ) and an ileal crypt (Extended Data Fig. 6ao ) from different individuals), occurring together and each accounting for over 150 mutations. To our knowledge, this is the first report that DNA editing of the human genome by APOBEC cytidine deaminases occurs in normal cells in vivo. The sequence context of these mutations in normal colon suggests that APOBEC3A is the major contributing enzyme 33 .
Four SBS signatures that do not match the reference set, SBSA, SBSB, SBSC and SBSD, were found in normal colorectal cells (SBSA has recently been reported in an oral squamous carcinoma 34 ). SBSA is characterized by T>C mutations at ATA, ATT and TTT, and T>G mutations at TTT. Its mutational burden correlated closely with that of IDA, in which single T deletions in short runs of T bases (with a modal average of four) predominate-suggesting that these two signatures are a result of the same underlying mutational process. SBSA was detectable in 29 out of 42 individuals and often accounted for thousands of mutations in just a subset of crypts. It clustered spatially in the colon, with crypts from the same biopsy exhibiting the signature even though the mutations themselves were not shared (Supplementary Information, Extended Data Fig. 9 ). Around 2.5-fold more T>C mutations occurred when the T base was on the transcribed than on the untranscribed strand. Transcriptional-strand bias is often caused by transcription-coupled nucleotide excision repair acting on DNA that has been damaged by exogenous exposures that cause covalently bound bulky adducts; however, it can also occur as a result of transcription-coupled DNA damage 35 . Assuming that one of these two possibilities is the case, damage to adenine underlies SBSA. To investigate the timing of SBSA, we constructed phylogenetic trees of mutations and established the mutational signatures in each branch ( Fig. 3 , Extended Data Fig. 6 ). SBSA was confined to early branches of these phylogenies (when these were available for analysis) ( Fig. 3b , Extended Data Fig. 6f , h, z, aa, am, ao, aq). Using the number of SBS1 mutations as indicators of real time, the mutational process that underlies SBSA appears to be active before an individual reaches 10 years of age (Supplementary Methods, Extended Data Fig. 6aq ). SBSA may therefore be caused by an extrinsic, locally acting and patchily distributed mutagenic insult that occurs during childhood. SBSB was characterized by C>T mutations at ACA, T>A at CTN and T>G at GTG, and was present in subsets of crypts from four individuals (Extended Data Fig. 6e , aa, ai, aj). It accounted for variable numbers of substitutions, with a maximum of 3,002 in one crypt ( Fig. 3c , Extended Data Fig. 6ai ). In the two individuals in whom SBSB could be timed (Extended Data Fig. 6aa , ai, aq), it appeared-as with SBSA-to be most active in the first decade of life. SBSB correlated with DBS8 and IDB ( Fig. 3c , Extended Data Fig. 9 ), suggesting that they are caused by the same underlying mutational process. DBS8 is composed of AC>CA and AC>CT mutations and has previously been reported in rare hypermutated cancers with no obvious cause 2 . IDB is dominated by deletion of a single T that has no other T bases surrounding it.
SBSC is characterized by one C>T mutation in CC dinucleotides. It primarily affected three crypts (with 1,050, 827 and 695 mutations, respectively) from the left colon of one individual with an unremarkable history (Extended Data Fig. 9 , Extended Data Fig. 6m , Supplementary  Table 1 ).
All crypts from a 66-year-old man carried many thousands of mutations of SBSD ( Fig. 3d , Extended Data Fig. 6ap ), which is characterized by T>A substitutions with a transcriptional-strand bias that is compatible with damage to adenine. This individual had been treated with multiple chemotherapeutic agents (cyclophosphamide, doxorubicin, vincristine, prednisolone, chlorambucil, bleomycin and etoposide) for lymphoma and subsequently developed caecal adenocarcinoma. SBSD resembles SBS25 (cosine similarity, 0.9), which has previously been found in Hodgkin's lymphoma cell lines from two patients who were treated with chemotherapy 31, 36 . To our knowledge, this is the first time that the mutational consequences of chemotherapy have been demonstrated in normal human cells in vivo. The mutational burden in the colorectal epithelium of this individual was three-to fivefold higher than that expected for his age-thus by extrapolation equivalent to that of a 200-300-year-old.
Copy-number changes and structural variants
Copy-number changes and/or structural variants were found in 80 out of 449 (18%) crypts that could be evaluated. Five crypts exhibited eight whole-chromosome copy-number increases that affected the same three chromosomes-3, 7 and 9-as well as the X chromosome (Extended Data Fig. 7a ). Thus, copy-number increases clustered in certain crypts and tended to affect certain chromosomes. No whole-chromosome losses were observed. Arm-level copy-number increases that affect chromosome 7 are common in colorectal cancers 37 and adenomas 38 . Copy-number increases in chromosomes 3 and 9 are seen in colorectal cancers, but are almost as frequently deleted 37 . Copy-neutral loss of heterozygosity (CN-LOH) was observed in 12 crypts, and affected chromosomes 1p, 6p, 7p, 8q, 9q, 10q (twice), 17p, 17q, 18q, 21q and 22q (Extended Data Fig. 7c ). CN-LOH is frequently observed in colorectal cancers, although the specific changes that we observe here are not recurrent features 39 . Five copy-number changes could be timed and all were estimated to have occurred in adulthood (Extended Data Fig. 7b ). Two changes that affected the same crypt appeared to be synchronous (Supplementary Information). An analysis of structural variants detected 48 large deletions, 18 tandem duplications, 4 translocations and 2 inversions (Extended Data Fig 7d, Supplementary Information) . Each structural variant was restricted to a single crypt, except for one deletion that was present in two adjacent crypts that share few mutations, indicating that it occurred during gestation or early childhood.
Driver mutations
Driver mutations are those that confer a selective advantage during cancer evolution. To search for driver mutations in normal colon, the whole-genome sequences of 571 crypts were supplemented with targeted sequencing of 90 known colorectal cancer genes ( Supplementary  Table 4 ) in additional crypts. In total, substitutions in these genes could be evaluated in 1,403 crypts and indels in 1,046. Statistical analysis provided evidence of positive selection on the recessive cancer genes AXIN2 (three truncating mutations; adjusted q value, 0.004) and STAG2 (two truncating mutations; adjusted q value, 0.038) indicating that these mutations are probably drivers. Additional mutations that are likely to be drivers were identified in cancer genes with canonical missense hotspot mutations. Nine hotspot mutations in PIK3CA (E542K, R38H), ERBB2 (R678Q, V842I, T862A), ERBB3 (R475W, R667L) and FBXW7 (R505C, R658Q) were observed (Extended Data Fig. 8 ). Given the specificity of these hotspot mutations, most are likely to be drivers. In addition, heterozygous truncating mutations were found in the recessive cancer genes ARID2, ATM (two), ATR, BRCA2, CDK12 (two), CDKN1B, RNF43 (two), TBL1XR1 and TP53 (Supplementary Table 5 ). There was no statistical evidence for selection of truncating mutations in the set of 90 colorectal cancer genes overall. The possibility that some have conferred a growth advantage, however, is not excluded. None of the analysed crypts carried more than one putative driver mutation.
Twenty-three pairs of adjacent crypts shared over 100 SBS1 mutations and thus were probably generated by postnatal fission of crypts. Two pairs carried driver mutations (one nonsense mutation in AXIN2 and one E542K in PIK3CA), although the association of driver mutations with crypt fission is not significant (P = 0.17). In one sister crypt the AXIN2 mutation was rendered homozygous by CN-LOH of chromosome 17q, which demonstrates that clonal evolution is ongoing in normal colon (Figs. 4, 3b ).
On the basis of the conservative assumption that just the AXIN2 and STAG2 truncating mutations and the missense hotspot mutations in PIK3CA, ERBB2, ERBB3 and FBXW7 are drivers, around 1% of normal colorectal crypts (approximately 150,000 crypts) in a 50-60-year-old individual (the mean age of crypts that were assessed for driver mutations in our cohort was 53 years) carry a driver mutation. As around 40% of people over 70 years old have an adenoma on colonoscopy 40 and (E542K)  SBS_X0  SBS1  SBS5  SBS18  SBS2  SBS13  SBSD  SBSA  SBSB  SBSC  DBS_X0  DBS2   DBS4  DBS6  DBS9  DBS11  DBS8  ID_X0  ID1  ID2  ID5  IDA  IDB   SBS Article around 5% of people develop colorectal cancer over their lifetime 41 (and some of these may arise from more recently acquired driver mutations) only an extremely small proportion of these crypt microneoplasms become a macroscopically detectable adenoma (less than 1 in 375,000) or carcinoma (less than 1 in 3 million) within the following few decades.
Clonal dynamics of normal epithelium
The distribution of allele fractions of mutations within the crypt informs on the dynamics of turnover of the crypt stem cells. We estimate that the average time since the most recent common ancestor of crypts is 5.5 years (95% confidence interval, 1-10.5), which is similar to previous estimates 14 . Our data are compatible with previous estimates of 7 active stem cells and 1.3 stem cell replacements per year 14 , or 5 stem cells and 0.6 stem cell replacements per year 42 , but we cannot exclude the possibility of a larger number of stem cells that turn over more frequently (Extended Data Fig. 10, Supplementary Information) . The microdissection approach also enabled us to investigate the clonal structure of colonic epithelium beyond the crypt. By comparing the genetic relatedness of crypts with their spatial relatedness, we estimate that crypts undergo fission at a mean rate of once every 27 years (95% confidence interval, 15.9-47.6) (Extended Data Fig. 10 , Supplementary Information).
Comparisons with colorectal cancer
There are marked differences between the genomes of normal colorectal stem cells and those of colorectal cancers. The total mutational burdens of substitutions (10,000-20,000) and indels (1,000-2,000) that are found in most colorectal carcinomas 2 (excluding those with hypermutator phenotypes, in which the burden is usually more than 10-fold higher) are higher than the approximately 3,000 substitutions and 300 indels that are found in most normal crypts from 50-60-year-old individuals (Extended Data Fig. 11a ). These differences may be underestimated, as the most recent common ancestor of cancers probably predates that of normal crypts. The high mutational burdens and associated mutational signatures of DNA mismatch repair deficiency and/or mutations in DNA polymerase ε or δ were not found in any normal colorectal crypts, but are present in around 20% of colorectal cancers. Equally striking is the difference between the 0-4 structural changes per normal crypt (with the majority having none; Supplementary Information) and the tens to hundreds per colorectal cancer 43 . In all of these respects, the genomes of normal crypts with driver mutations were similar to those of normal crypts without drivers (Extended Data Fig. 9 ).
There was no difference in the burden of either sporadic or ubiquitous mutational processes between the crypts of individuals with and without a colorectal cancer (Supplementary Information). If differences in mutational processes in normal cells do underlie why some people develop colon cancer and others do not, these mutational processes must affect only a small proportion of crypts in the colon, or only exert subtle effects on the rate of mutation, such that we could not detect differences between the two groups. The increased base substitution and indel mutation loads in cancers are due to a combination of higher burdens of the ubiquitous mutational signatures found in normal crypts, additional signatures thus far found exclusively in cancers (confirming previous reports 5, 44 ) and more copy-number changes and structural variation (Extended Data Fig. 11a ). The causes of some of these additional mutations in cancer are known (for example, defective mismatch repair and mutations in DNA polymerase ε or δ) but the majority are uncertain.
The relative frequencies of mutated cancer genes differ between colorectal adenomas or carcinomas and normal colorectal cells (P = 0.003; Supplementary Information, Extended Data Fig. 11a ). Mutations in APC, KRAS and TP53 are common in colorectal cancer 37 -accounting for 56% of base-substitution and indel driver mutations (Supplementary Methods)but comparatively rare among normal crypts with driver mutations (1 in 14) . By contrast, mutations in, for example, ERBB2 and ERBB3 are common in normal crypts with driver mutations (5 in 14), but rare in colorectal cancer (7 in 631). In the case of APC (but not KRAS, and perhaps not TP53), biallelic inactivation may be required to confer a strong growth advantage; this helps to explain why APC may be mutated less frequently in normal colon than ERBB2 or ERBB3 (which require a single hit to do so). The results suggest that mutations in APC, KRAS and TP53 confer higher likelihoods of conversion to adenoma and carcinoma than mutations in ERBB2 and ERBB3, whereas the latter confer higher likelihoods of crypt colonization by stem cells. There was no detectable difference in the frequency of driver mutations between individuals in our cohort who had colorectal cancer and those who did not (Supplementary Information).
Discussion
This study has characterized all classes of somatic mutation in hundreds of normal colorectal epithelial stem cells. Our experimental design allows us to gain insights into different facets of the earliest stages of the clonal evolution of colorectal cancers; namely, the range of mutational processes, the frequency of driver mutations and the clonal dynamics of colonic stem cells.
A substantial repertoire of base-substitution and indel mutational processes is operative (some of which are ubiquitous and some sporadic), together with relatively infrequent copy-number changes and genome rearrangements. DNA editing by APOBEC cytidine deaminases occurs in normal colon, albeit only rarely. Many signatures, however, are of unknown aetiology and some appear to be acquired early in life. The presence of five times the age-standard mutational load in all colorectal cells-and potentially many other tissues-in an individual who had undergone chemotherapy provides new insight into the effect of such exposures, and raises questions pertaining to the relationship between mutational load and the relatively modest effect of chemotherapy on cancer risk 45 .
Herein, we have revealed the earliest stages of colorectal cancer development. They are characterized by numerous crypts that carry driver mutations, of which only a very small fraction ever manifest as macroscopic neoplasms. Certain mutated cancer genes appear to foster this pervasive and invisible wave of microneoplastic change, whereas others particularly engender progression to colorectal adenoma and cancer. The conversion of these early microneoplasms to more advanced stages of colorectal neoplasia is associated with the acquisition of increased mutational loads that are composed of base substitutions, indels, structural variants and copy-number changes. More extensive studies of colorectal epithelium will enable the rarer intermediate stages between these early clones and small adenomas to be characterized, and will refine our understanding of the development of the subset of microneoplasms that are more likely to become carcinomas.
The proportion of normal colorectal epithelial cells with driver mutations (1%) is, however, substantially lower than that of other normal tissues so far studied-notably skin (30%) 10 and oesophagus (over 50%) 16 . This may be, at least in part, a consequence of the modular structure of glandular epithelia. The small number of stem cells within a crypt diminishes the probability that a cell with a driver mutation will outcompete its wild-type neighbours. Moreover, even if it does colonize the crypt, a mutant stem cell is entombed in it unless the cell can overcome the largely unknown forces that control clonal expansion through crypt fission. The lower burden of driver mutations in colon relative to endometrium 11, 15 (which is also glandular) remains to be investigated.
Fundamental questions are being addressed with respect to differences in the incidence rates of cancer between tissues. The somatic mutational burden in colon and ileum is similar despite the substantially higher incidence of cancer in colon (as previously noted 4 ), and therefore does not appear to account for this difference. Whether the total burden of microneoplastic change across the colon and in other tissues more closely correlates with these differences is yet to be determined.
Finally, this study provides a reference perspective on the mutational signatures and driver mutations in normal colon, against which disease states of inflammatory, genetic, neoplastic, degenerative and other aetiologies can be compared. Similar surveys conducted across the range of normal cell types will inform on the universal process of somatic evolution in the human body in health and disease.
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Methods
Data reporting
No statistical methods were used to predetermine sample size. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment.
Human tissues
We obtained healthy colonic biopsies from four cohorts (Supplementary Table 1 ). The first represents seven deceased organ donors ranging in age from 36 to 67, from whom colonic and small-intestinal biopsies were taken at the time of organ donation (REC 15/EE/0152). The second represents individuals aged 60 to 72 who were having a colonoscopy after a positive faecal occult blood test as part of the bowel cancer screening programme (Ethical approval 08-H0308-13); we selected 16 individuals who were not found to have either an adenoma or a carcinoma on colonoscopy, and 15 who were found to have a colorectal carcinoma (the normal biopsies that we used were distant from these lesions). The third cohort represents three paediatric patients who underwent routine colonoscopy to exclude inflammatory bowel disease and who were found to have a completely normal intestinal mucosa macroscopically and histologically (REC 12/EE/0482). The final cohort comprised one 78-year-old man with oesophageal cancer who underwent a rapid autopsy (REC 13/EE/0043). This individual had been treated with palliative chemotherapy of epirubicin, oxaliplatin and capecitabine within the three months before death; given that monoclonal conversion within crypts takes place on the scale of years, mutations caused by these chemotherapies are likely to be restricted to a small proportion of stem cells per crypt and so unlikely to be detected. All samples were obtained with informed consent and the studies were approved by East of England Research Ethics Committees.
Laser-capture microdissection of colonic crypts
Fresh frozen biopsies were embedded in optimal cutting temperature compound. Sections of 30 µm were fixed in methanol for 5 min, washed three times with phosphate-buffered saline and stained with Gill's haematoxylin for 20 s. Crypts were isolated by laser-capture microdissection, and collected in separate wells of a 96-well plate. They were lysed using the Arcturus PicoPure Kit (Applied Biosystems) according to the manufacturer's instructions. DNA library preparation then proceeded without clean-up or quantification.
Library preparation
Two library-preparation methods were used for laser-capture microdissected material: in initial experiments, sonication was used to fragment DNA; and later, an enzymatic fragmentation method was implemented as it could make libraries from even lower input. Comparison of the two methods showed no difference in mutation calls once post-processing filters (described below) had been implemented. All samples in this study were processed using an Agilent Bravo Workstation (Option B; Agilent Technologies).
For sonication libraries, lysate from laser-capture microdissection (20 µl) was mixed with 100 µl TE buffer 1(0 mM Tris-HCl, 1 mM EDTA) (Ambion) and DNA was fragmented using focused acoustics (Covaris LE220; Covaris, Inc.). Fragmented DNA was mixed with 80 µl Ampure XP beads (Beckman Coulter). After a 5-min binding reaction and magnetic bead separation, genomic DNA was washed twice with 75% ethanol. Beads were resuspended in 20 µl nuclease-free water (Ambion) and processed immediately for DNA library construction. Each sample (20 µl) was mixed with 2.8 µl NEBNext Ultra II End Prep Reaction Buffer and 1.25 µl NEBNext Ultra II End Prep Enzyme Mix (New England BioLabs), and incubated on a thermal cycler for 30 min at 20 °C then 30 min at 65 °C. Following DNA fragmentation and A-tailing, each sample was incubated for 20 min at 20 °C with a mixture of 30 µl ligation mix and 1 µl ligation enhancer (New England BioLabs), 0.9 µl nuclease-free water (Ambion) and 0.1 µl duplexed adapters (100 µM; 5′-ACACTCTTTCCCTACACGAC GCTCTTCCGATC*T-3′, 5′-phos-GATCGGAAGAGCGGTTCAGCAGGAATG CCGAG-3′). Adapter-ligated libraries were purified using Ampure XP beads by addition of 65 µl Ampure XP solution (Beckman Coulter) and 65 µl TE buffer (Ambion). After elution and bead separation, DNA libraries (21.5 µl) were amplified by PCR by addition of 25 µl KAPA HiFi HotStart ReadyMix (KAPA Biosystems), 1 µl PE1.0 primer (100 µM; 5′-AATGAT ACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGA TC*T-3′) and 2.5 µl iPCR-Tag (40 µM; 5′-CAAGCAGAAGACGGCATACG AGATXGAGATCGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATC-3′), in which 'X' represents one of 96 unique 8-base indexes The sample was then mixed and thermal-cycled as follows: 98 °C for 5 min, then 12 cycles of 98 °C for 30 s, 65 °C for 30 s, 72 °C for 1 min and finally 72 °C for 5 min. Amplified libraries were purified using a 0.7:1 volumetric ratio of Ampure Beads (Beckman Coulter) to PCR product and eluted into 25 µl nuclease-free water (Ambion). DNA libraries were adjusted to 2.4 nM and sequenced on the HiSeq X platform (Illumina) according to the manufacturer's instructions, with the exception that we used iPCR-Tag (5′-AAGAGCGGTTCAGCAGGAATGCCGAGACCGATCTC-3′) to read the library index.
For enzymatic fragmentation, lysate from laser-capture microdissection (20 µl) was mixed with 50 µl Ampure XP beads (Beckman Coulter) and 50 µl TE buffer (10 mM Tris-HCl, 1 mM EDTA) (Ambion) at room temperature. After a 5-min binding reaction and magnetic bead separation, genomic DNA was washed twice with 75% ethanol. Beads were resuspended in 26 µl TE buffer and the bead-genomic DNA slurry was processed immediately for DNA library construction. Each sample (26 µl) was mixed with 7 µl 5X Ultra II FS buffer and 2 µl Ultra II FS enzyme (New England BioLabs), and incubated on a thermal cycler for 12 min at 37 °C then 30 min at 65 °C. Following DNA fragmentation and A-tailing, each sample was incubated for 20 min at 20 °C with a mixture of 30 µl ligation mix and 1 µl ligation enhancer (New England BioLabs), 0.9 µl nuclease-free water (Ambion) and 0.1 µl duplexed adapters (100 µM; 5′-ACACTCTTTCCCTACACGACGCTCTTCCGATC*T-3′, 5′-phos-GATCGG AAGAGCGGTTCAGCAGGAATGCCGAG-3′). Adapter-ligated libraries were purified using Ampure XP beads by addition of 65 µl Ampure XP solution (Beckman Coulter) and 65 µl TE buffer (Ambion). After elution and bead separation, DNA libraries (21.5 µl) were amplified by PCR by addition of 25 µl KAPA HiFi HotStart ReadyMix (KAPA Biosystems), 1 µl PE1.0 primer (100 µM; 5′-AATGATACGGCGACCACCGAGATCTACACTC TTTCCCTACACGACGCTCTTCCGATC*T-3′) and 2.5 µl iPCR-Tag (40 µM; 5′-CAAGCAGAAGACGGCATACGAGATXGAGATCGGTCTCGGCATTCCT GCTGAACCGCTCTTCCGATC-3′), in which 'X' represents one of 96 unique 8-base indexes. The sample was then mixed and thermal-cycled as follows: 98 °C for 5 min, then 12 cycles of 98 °C for 30 s, 65 °C for 30 s, 72 °C for 1 min and finally 72 °C for 5 min. Amplified libraries were purified using a 0.7:1 volumetric ratio of Ampure Beads (Beckman Coulter) to PCR product and eluted into 25 µl nuclease-free water (Ambion). DNA libraries were adjusted to 2.4 nM and sequenced on the HiSeq X platform (Illumina) according to the manufacturer's instructions, with the exception that we used iPCR-Tag (5′-AAGAGCGGTTCAGCAGGAATG CCGAGACCGATCTC-3′) to read the library index.
Whole-genome sequencing
We generated paired-end sequencing reads (150 bp) using Illumina XTEN® machines, resulting in a coverage of around 15× per sample. In 94% of the whole-genome-sequenced crypts that were included for statistical analysis, over 90% of the callable genome was covered by more than 10 reads. Sequences were aligned to the human reference genome (NCBI build37) using BWA-MEM.
Targeted sequencing A 2.3-Mb capture panel was designed in-house to pull down genes that are known or suspected to play a role in neoplasia. We performed custom RNA bait design following the manufacturer's guidelines (SureSelect; Agilent). Samples were multiplexed on flow cells and subjected to pairedend sequencing (75-bp reads) using Illumina HiSeq2000 machines. One 96-well plate of samples was sequenced on each lane, but as tissue recovery was variable, a range of coverage was achieved. Sequences were aligned to the human reference genome (NCBI build37) using BWA-align.
Calling substitutions
Substitution calling was broken down into three steps: mutation discovery; filtering to produce a list of clean sites; and genotyping, in which the presence or absence of every mutation in every sample is evaluated.
First, mutations were discovered using the cancer variants through expectation maximization (CaVEMan) algorithm 46 . CaVEMan uses a naive Bayesian classifier to derive the probability of all possible genotypes at each nucleotide. CaVEMan copy-number options were set to major copy number 5 and minor copy number 2 for normal clones, as in our experience this maximizes sensitivity. The algorithm was run using an unmatched normal to be able to derive phylogenies: had another sample from the same individual been treated as a matched normal, early embryonic mutations would have been treated as germline and discarded, resulting in incorrect trees.
Second, a number of post-processing filters were applied. These included filtering against a panel of 75 unmatched normal samples to remove common single-nucleotide polymorphisms (SNPs), postprocessing as described previously 32 and two filters (only applied to whole-genome-sequencing data) designed to remove mapping artefacts associated with BWA-MEM: the median alignment score of reads supporting a mutation should be greater than or equal to 140, and fewer than half of these reads should be clipped. The library-preparation protocol for microbiopsies produced shorter library insert sizes than standard methods. Reads could therefore overlap, resulting in double counting of mutant reads. Fragment-based statistics were generated to prevent the calling of variants that were supported by a low number of fragments. Variants were annotated by ANNOVAR 47 and fragment-based statistics (fragment coverage, number of fragments supporting the variant, fragment-based allele fraction) were calculated for each variant after the exclusion of marked PCR duplicates. In the rare event of discordance in the called base at the variant position between overlapping paired-end reads, the base with the highest-quality score was selected. Fragmentbased statistics were calculated separately for high-quality fragments (alignment scores greater than or equal to 40 and base scores greater than or equal to 30) . Variants that were supported by at least three-high quality fragments were retained and used for the next stage of variant filtering. Inspection of variants specific to laser-capture microdissection experiments revealed that the vast majority were present within inverted repeats capable of forming hairpin structures, that they were supported by reads with very similar alignment start position (and so not marked as PCR duplicates) and were primarily located close to the alignment start within the supporting reads. These variants commonly coincided with other proximal variants (1-30 bp), but filtering based on variant proximity would also remove actual kataegis events. In silico modelling of the potential hairpin showed that the variants were aligning to each other in the stem of the structure, but could not form a base pair, whereas all other bases could. The artefacts are probably the consequence of erroneous processing of cruciform DNA (either existing before DNA isolation or formed during library preparation) by the enzymatic digestion protocol applied. We considered modelling the hairpin structures to filter these variants, but given the fact that read clustering (i.e., similar alignment position) serves as a hallmark for these artefacts, we opted to use the proximity of the variant to the alignment start, and the standard deviation (s.d.) and median absolute deviation (MAD) of the variant position within the supporting reads, as features for filtering. These statistics were calculated separately for reads aligned to positive and negative strands. In cases in which the variant was supported by a low number of reads (i.e., 0-1 reads) for one of the strands, the filtering was based only on the statistics generated for the other strand. Per variant, if one of the strands had too few supporting reads, it was required for the other strand that either: i) there should be 90% or more supporting reads to report the variant within the first 15% of the read starting from the alignment start; or ii) the statistics MAD > 0 and s.d. > 4. Per variant, if both strands were supported by sufficient reads it was required for both strands separately that: i) there should be 90% or more supporting reads to report the variant within the first 15% of the read; ii) the statistics MAD > 2 and s.d. > 2; or iii) the other strand should have the statistics MAD > 1 and s.d. > 10 (i.e., the variant is retained if the other strand demonstrates strong measures of variance). In our experience, the proposed strategy greatly reduces the number of artefactual variants while retaining all other variants-as assessed by running the last filtering step on whole-genome-sequencing data from experiments that were not laser-capture microdissections.
Third, mutations were genotyped in every sample. A pile-up of all the samples from a given individual was constructed, in which the numbers of mutant and wild-type reads in every sample over every site that had been called in any sample from that person were counted. Only reads with a mapping quality of 30 or above and bases with a base quality of 30 or above were counted. After applying these filters, mutations were genotyped on the basis of the number of mutant and wild-type reads at each locus. Mutations were called on the basis of a VAF greater than 0.2, a depth greater than 7 and at least 4 mutant reads. If the depth over a locus was less than 7 in a given sample, or if there was more than one mutant read but the other criteria were not met, the genotype was set to NA (not applicable) for tree-construction purposes. Loci that were set to NA in more than one third of the samples were removed for construction of the phylogeny. Positions were called as germline if they were either called as present or NA in all of the samples from a given individual. Around 1.2% of all mutations were present in the coding regions of the genome. All mutations in coding regions are provided ( Supplementary  Table 3 ).
Calling short indels
As for substitutions, calling of indels was broken down into mutation discovery, filtering and genotyping. Mutations were called with the Pindel algorithm 48 using an unmatched normal. Post-processing filters were applied as described previously 32 , and the number of mutant and wild-type reads was tabulated as above. The same dataset-specific filters were applied as for substitutions. Indels were then genotyped on the basis of a VAF greater than 0.2, a depth of at least 10 and support of at least 5 mutant reads.
Calling structural variants
Genomic rearrangements were called using the BRASS algorithm (https://github.com/cancerit/BRASS). Abnormally paired read pairs from whole-genome sequencing were grouped and filtered by read remapping. Read-pair clusters for which more than 50% of the reads mapped to microbial sequences were removed, as were rearrangements for which the breakpoint could not be reassembled. Candidate breakpoints were matched to copy-number breakpoints defined by ASCAT (see below) within 10 kb. Only structural variants in which the two breakpoints were more than 1,000 base pairs apart were considered. Structural variants were called against a matched normal skin or blood sample when available and against another crypt from the same individual with good coverage when not.
Calling copy number
Copy-number changes were called using the allele-specific copy number analysis of tumours (ASCAT) algorithm 49 . The same matched normal sample was used as for calling structural variants. For additional validation of copy-number changes in normal colon, the QDNAseq algorithm 50 was run. ASCAT uses both the read depth and ratios of heterozygous SNPs to determine an allele-specific copy number, whereas QDNAseq relies solely on variations in sequencing coverage. To call amplifications Article and deletions in the colonic microbiopsy cohort, only those that both were called by ASCAT and showed a clear departure from the background log 2 -transformed ratio by QDNAseq were retained. To call CN-LOH in this cohort, all such events called by ASCAT were checked visually on JBrowse 51 to verify an imbalance of parental SNPs. Only crypts with a coverage of more than 10×, for which copy-number changes could be reliably detected, were used.
Detection of driver variants and positive selection
Driver mutations were detected through both an unbiased dN/dS method and manual annotation. For these analyses, the CaVEMan and Pindel calls were used without post-processing filters (such as requiring a VAF cut-off of greater than 0.2) to maximize our sensitivity. All putative driver variants were visually inspected using JBrowse 51 , thus we could afford a higher false-positive rate in the mutation discovery phase.
The statistical model dNdScv 52 was used to conduct three tests: first, using only the whole-genome-sequencing data, an analysis of selection over all genes; second, using combined whole-genome and targetedsequencing data, over all the genes covered by the bait set; and finally, again using this combined dataset, over 90 selected cancer genes (Supplementary Table 4 , Supplementary Information).
Manual annotation of driver variants on the basis of previous knowledge complemented this. A list of 90 colorectal cancer genes (appendix) curated from the literature that were also covered by the bait set were intersected with the list of substitutions and indels from combined whole-genome and targeted sequencing. Mutations were annotated as putative drivers either if they were missense mutations that fell in an oncogene hotspot (on the basis of visualization of the distribution of mutations in the gene on COSMIC 53 ), or if they were truncating mutations that fell in a tumour suppressor gene.
Structural variants that might act as drivers were assessed by intersection of genes involved in each structural variant with the twelve genes involved in gene fusions that have been reported in colorectal cancer in COSMIC (VTI1A, TCF7L2, TPM3, NTRK1, PTPRK, RSPO3, ETV6, NTRK3, EIF3E, RSPO2, C2orf44 and ALK). No fusion genes were found. None of the genes involved in structural variants in our data overlapped with the list of 90 cancer genes used for assessing substitutions and indels, and there were no genes that were affected by more than one structural variant. No high-level copy-number amplifications were observed and there were no homozygous deletions.
Note that the frequency of driver mutations is low and as such we cannot estimate a per-gene driver frequency. All we can do to derive a meaningful estimate is to pool our driver mutations. In addition, coverage may fluctuate even within a gene. Some portions of a gene may be well-covered in 1,000 crypts, and others in 2,000 crypts. The approach that we took was to calculate, for the average exonic base pair in our 90 cancer genes, the number of crypts in which that base pair was covered by 8 or more reads (for substitutions) and by 10 or more reads (for indels). Of all bases in the targeted panel across all crypts, 64% are covered by 8 or more reads, which equates to a number of callable bases equivalent to having sequenced about 1,400 crypts with perfect coverage over every base in every crypt. This average number of crypts in which all base pairs achieve good coverage becomes the denominator for calculating the frequency of driver mutations (with the number of drivers observed in the dataset as the numerator). A similar approach can be taken with indels. Our estimate of 1% uses a global correction, on the assumption that under-representation and over-representation will even itself out when estimating the total frequency of driver mutations in the whole dataset.
Estimation of the frequency of driver mutations in cancer
Publicly available colorectal cancer mutation calls were obtained from The Cancer Genome Atlas (TCGA) network 37 . Driver mutations were annotated manually in the same way as in our dataset: only mutations that fell in the 90 genes that we had selected were considered, and they were annotated as putative drivers either if they were missense mutations that fell in an oncogene hotspot (on the basis of visualization of the distribution of mutations in the gene on COSMIC 53 ), or if they were truncating mutations that fell in a tumour suppressor gene.
Construction of phylogenies
Phylogenies are used in this analysis for timing mutations. The most informative branches in this case are the long branches shared by a small number of crypts, which are very robust to all methods of tree construction. Trees were built using maximum parsimony, with substitutions called as described above. For every individual, the input matrix of mutation calls was bootstrapped 100 times. Phylogenies were constructed for each replicate using the Wagner method of the Mix programme from the PHYLIP suite of tools 54 . The consensus phylogeny was constructed from 100 bootstrap runs using the extended majority rule method for the Consense programme from the PHYLIP suite of tools 54 .
Across all phylogenies, a mean of 10% and a median of 1.5% of mutations per tree did not fit the trees perfectly. Phylogenies with more crypts had more mutations that fitted imperfectly. Consider a mutation that is actually present in 50 crypts. Even with 15× coverage over the site in every sample, and with every crypt completely clonal, if we simulate resampling of mutant reads from the binomial distribution (with size of 15 and probability of 0.5), 17% of the time the mutation will have fewer than the 3 reads required to call it in at least one sample. Variation in sequencing depth, clonality and sequencing errors would further decrease the probability of calling the mutation perfectly in every sample. Nodes across all our phylogenies had mean bootstrapping values of 0.77 and median bootstrapping values of 0.99. Branches at the very top of the phylogenies, which probably represent embryonic cell divisions, are supported by only a few mutations and have lower support because in a given bootstrap sample the couple of mutations that support this node may be omitted. Longer shared branches almost always have bootstrapping values of 1. These longer shared branches are those that are most important to our analyses, because they are the most informative when timing mutational signatures relative to one another and because they represent postnatal crypt fission events. To further increase our confidence in our phylogenies, we validated them by reconstructing them with indels. To do this, the same procedure as for substitutions was followed for indel matrices. As there were fewer indels than substitutions, nodes in indel phylogenies were generally reconstructed with lower confidence than in substitution phylogenies, but they broadly agree. Of the nodes reconstructed with 90% or greater confidence in the indel tree, 85% were present with exactly the same set of descendants in the substitution trees. Any errors in the phylogenies should be relatively minor and not affect our downstream analyses.
The program that was used for inferring phylogeny provided the topology of the tree but not the assignment of mutations. Mutations from the input matrix of genotypes therefore have to be reassigned to branches. To assign a set of mutation calls with no false negative and no false positives to a tree, each branch of the tree was considered in turn. If a mutation was called in all the descendants of a given branch, and in no samples that were not descendants of the branch, mutations were assigned to that branch. Some colonic microbiopsies had low coverage and stromal contamination. For this reason, we did not expect mutations to fit the tree perfectly, as a mutation that was truly present in a colony might be missed if too few supporting reads are found. Mutations were only assigned to the tree to determine the mutational processes active at a particular time. We reasoned that it was preferable to assign only mutations that fit the tree perfectly and adjust the branch lengths based on the power to call mutations at a given branch, rather than attempting to assign mutations that fit the tree imperfectly. Using the clonality and coverage of all descendants of a branch, the proportion of true substitutions or indels on the branch that would be first discovered (whether by CaVE-Man or Pindel) and then genotyped as present according to the criteria described above was calculated. The observed branch length was then adjusted by dividing by this proportion. Adjustment proportions can be found in Supplementary Table 7 . This was done for both substitutions and indels, but not for structural variants and for larger copy-number changes, owing to a lack of data: most branches have no large variants and so could not be extended appropriately. Rearrangements and copynumber changes were assigned to phylogenies manually.
Extraction of mutational signatures
Mutational signatures were extracted using the mutations assigned to every branch of a phylogeny as a 'sample'. This allows better discrimination of mutational processes that may occur at different times within the same cell. Mutations were categorized following the method used by the Mutational Signatures working group of the PCAWG 2 . Singlebase substitutions were categorized into 96 classes according to the identity of the pyrimidine-mutated base pair, and the base 5′ and 3′ to it. Doublet-base substitutions were categorized into 78 classes according to the identity of the reference and alternative bases. Indels were classified into 83 classes according to whether they were an insertion or a deletion, the identity of the inserted or deleted base, the length of the mononucleotide tract in which they occurred and the degree of homology with the surrounding sequence ( Fig. 1a ).
Signatures were extracted using a hierarchical Dirichlet process (HDP) 55 (https://github.com/nicolaroberts/hdp). Code and the input mutations are provided at https://github.com/HLee-Six/colon_microbiopsies. First, the algorithm was conditioned on the set of mutational signatures that have found to be operative in colorectal cancers in PCAWG 2 : SBS1, SBS2, SBS3, SBS5, SBS13, SBS16, SBS17a, SBS17b, SBS18, SBS25 (included although it is not found in colorectal cancer because the similarity with the mutational profile with crypts from one individual had been previously noted), SBS28, SBS30, SBS37, SBS40, SBS41, SBS43, SBS45, SBS49, DBS, DBS3, DBS4, DBS6, DBS7, DBS8, DBS9, DBS10, DBS11, ID1, ID2, ID3, ID4, ID5, ID6, ID7, ID8, ID10 and ID14. This allows simultaneous discovery of new signatures and matching to known ones. Nine SBS, two DBS and five ID signatures were discovered (Extended Data Fig. 2 ). Despite pre-conditioning, signatures that were perfectly correlated in all samples were still amalgamated. This occurred, for example, with SBS1, SBS5 and SBS18. Therefore, expectation maximization was used to deconvolute all HDP signatures into known PCAWG signatures. If a signature that was reconstituted from the components that expectation maximization extracted (only including PCAWG signatures that accounted for at least 10% of mutations in each sample to avoid overfitting) had a cosine similarity to the HDP signature of more than 0.95, the signature was presented as its expectation maximization deconvolution. Three HDP signatures met these criteria: the HDP SBS1 signature was deconvoluted into a mixture of PCAWG SBS1, PCAWG SBS5 and PCAWG SBS18; the HDP DBSA signature was deconvoluted into PCAWG DBS2, PCAWG DBS4, PCAWG DBS6, PCAWG DBS9 and PCAWG DBS11; and the HDP IDC signature was deconvoluted into PCAWG ID1, PCAWG ID2 and PCAWG ID5 (Extended Data Fig. 3) . To test the robustness of this signature analysis, other signature-extraction methods were used: HDP with no pre-conditioning, the non-negative matrix factorization (NMF) method used in a previous study 4 and a version of the NMF algorithm used by in another study 2 . These all produced comparable results (Extended Data Fig. 4 ).
Timing SBSA and SBSB throughout life
Five patients had informative clades with branch points that allowed us to time SBSA. Plotting the cumulative amount of SBSA versus SBS1 at each node in these clades (Extended Data Fig. 6aq ), we observed that for each, the rate of accumulation of SBSA relative to SBS1 was high in early branch points and then slowed down almost to zero on all branches but for one (a branch of patient ao; for this patient, SBSA continued to be acquired, albeit at a slow rate).
We can take the inflexion point on the graph of cumulative SBSA versus SBS1 to be the upper limit of the point in time when SBSA slowed down. This provides an upper bound for three reasons. First, when we observe the presence of a signature on a branch, we know that the causative process must have been active at some point during the lifetime of the branch, but we cannot say when on the branch it occurs; it might have ended long before the branch did. Second, if the time to the most recent common ancestor of the crypt is longer than 0, the age at which this stopped would be earlier. Third, if the SBS1 mutation rate is increased in early life-as it may be during the rapid growth of the embryo-the age at which the inflexion point occurs would be earlier.
Using these five informative clades, and assuming a clock-like but personalized rate of SBS1 accumulation (i.e., each patient can accumulate SBS1 at their own constant rate), we found that the upper bound of the age at which SBSA slowed was: 9.7 years (patient h); 7.1 years (patient z); 2.4 years (patient am); 20.1 years (patient aa); and 9.6 years (patient ao). There are no branches that begin after 10 years of age with a high ratio of SBSA to SBS1.
The most informative branch point is the earliest inflexion point; the estimate of 2.4 years from patient aa is therefore, perhaps, our best estimate. Nonetheless, we did not want to base our statement on a single patient, and so 10 years was given in the text as 4 patients had branches that ended before 10 years of age.
A similar argument can be made for SBSB (Extended Data Fig. 6aq ). For SBSB, however, only two clades were informative. The estimated upper bounds of age for SBSB activity were 2.4 years old (this was the same inflexion point as for SBSA in patient aa) and 6.4 years old (patient ai). For patient ai, a reasonable amount of SBSB is still acquired after this branch point. If the ratio of accumulation of SBSB versus SBS1 continued at the same rate as before this branch point, the number of SBSB mutations seen in the terminal branches would have been observed by 8.2 years of age.
Analysis of telomere length
Telomere length was estimated from whole-genome-sequencing data using Telomerecat. Telomerecat is a Python-based software package for estimating telomere length from short-read whole-genome-sequencing data 56 . It functions by classifying paired-end reads as either fully or partially telomeric on the basis of the canonical hexamer TTAGGG, and uses that ratio to estimate an average telomere length. Notably, Telomerecat measures telomeres and also accounts for interstitial telomeric repeats. It is ploidy and species agnostic (assuming that the telomere hexamer is the canonical mammalian signature of TTAGGG n ). Telomerecat has four main stages: 1) identification of all telomeric or partially telomeric read pairs and creation of a subsetted bam file that contains only these reads; 2) classification of telomeric read-pairs as intratelomeric, boundary, junction-spanning or intrachromosomal; 3) error correction of boundary or junction-spanning read pairs; and 4) estimation of telomere length based on the ratio of intratelomeric and boundary or junction-spanning read pairs.
Telomerecat has been validated on whole-genome DNA-sequencing files from both tumour and normal samples 56 . Its results show concordance with an established method of telomere length measurement, the mean telomere restriction fragment (mTRF) technique. Alternative packages are available, notably Computel 57 , Telseq 58 and TelomereHunter 59 . They all have respective strengths and have been benchmarked through their methods publications. We have opted for Telomerecat as it provides an estimate of telomere length at base-pair resolution, while also correcting for variations in sequencing depth in a ploidy-agnostic manner.
We ran Telomerecat on 445 crypt bam files with good coverage and clonality to generate estimates of telomere length. Telomerecat was threaded across 10 cores and 100 simulation cycles were requested per run. The values displayed are the median telomere length across all chromosomes in that sample, measured in base pairs. 1 nature research | reporting summary
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